SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Piramal Pharma - Quaterly Results

10 May 2024 Evaluate
The sales for the March 2024 quarter moved up 44.64% to Rs. 15253.00 millions as compared to Rs. 10545.80 millions during the corresponding quarter last year.The Net Profit of the company reported a remarkable increase of 554.87% to Rs. 2730.80  millions  from Rs. 417.00 millions in previous same quarter.Operating Profit saw a handsome growth to 4428.30 millions from 1524.30 millions in the quarter ended March 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 15253.00 10545.80 44.64 43901.10 34432.20 27.50 43901.10 34432.20 27.50
Other Income 531.90 628.80 -15.41 2020.60 3410.70 -40.76 2020.60 3410.70 -40.76
PBIDT 4428.30 1524.30 190.51 8199.80 4386.00 86.95 8199.80 4386.00 86.95
Interest 276.60 337.80 -18.12 1071.00 1158.70 -7.57 1071.00 1158.70 -7.57
PBDT 4151.70 1186.50 249.91 7128.80 3157.70 125.76 7128.80 3157.70 125.76
Depreciation 525.00 530.10 -0.96 2052.60 1920.80 6.86 2052.60 1920.80 6.86
PBT 3626.70 656.40 452.51 5076.20 1236.90 310.40 5076.20 1236.90 310.40
TAX 895.90 239.40 274.23 1164.00 541.90 114.80 1164.00 541.90 114.80
Deferred Tax 23.50 2.80 739.29 39.20 154.20 -74.58 39.20 154.20 -74.58
PAT 2730.80 417.00 554.87 3912.20 695.00 462.91 3912.20 695.00 462.91
Equity 13229.50 11933.20 10.86 13229.50 11933.20 10.86 13229.50 11933.20 10.86
PBIDTM(%) 29.03 14.45 100.86 18.68 12.74 46.63 18.68 12.74 46.63

Piramal Pharma Share Price

148.90 1.45 (0.98%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×